

## Special Issue

# Roles of Urokinase Receptors in Cell Biology: Modulating Tumor Cell Migration and Invasion

### Message from the Guest Editor

This Special Issue will provide a comprehensive overview of the role of the urokinase-type plasminogen activator receptor (uPAR) in tumor cell biology, with a particular focus on its function in cell migration, invasion, and metastasis. As a critical regulator of extracellular matrix remodeling and signaling pathways, uPARs have been implicated in various aspects of tumor progression, including epithelial-to-mesenchymal transition (EMT), angiogenesis, drug resistance, and immune evasion. An understanding of the molecular mechanisms governing uPAR activity may lead to the development of novel therapeutic strategies targeting invasive cancers. We welcome contributions from molecular biologists, oncologists, pharmacologists, computational biologists, and clinicians working on innovative therapeutic strategies and in silico modeling approaches targeting uPAR-driven tumor progression.

### Guest Editor

Prof. Dr. Agata Kabała-Dzik

Department of Pathology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Ostrogórska 30, 41-200 Sosnowiec, Poland

### Deadline for manuscript submissions

28 March 2026



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/235103](https://mdpi.com/si/235103)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)